INSP Stock Recent News
INSP LATEST HEADLINES
MINNEAPOLIS, April 21, 2025 (GLOBE NEWSWIRE) -- Inspire Medical Systems, Inc. (NYSE: INSP) (Inspire), a medical technology company focused on the development and commercialization of innovative, minimally invasive solutions for patients with obstructive sleep apnea (OSA), today announced that two leading physicians in the field of sleep medicine and sleep surgery, Paul T. Hoff, M.D., M.S., an otolaryngologist, and Ruchir P. Patel, M.D., F.A.C.P., a sleep medicine specialist, will join Inspire in Vice President, Senior Medical Director roles, effective April 21 and June 2 respectively.
MINNEAPOLIS, April 01, 2025 (GLOBE NEWSWIRE) -- Inspire Medical Systems, Inc. (NYSE: INSP) (Inspire) will release financial results for the first quarter 2025 after the close of trading on Monday, May 5. Inspire's management team will host a corresponding conference call beginning at 5:00 p.m.
MINNEAPOLIS, March 06, 2025 (GLOBE NEWSWIRE) -- Inspire Medical Systems, Inc. (NYSE: INSP) (Inspire), a medical technology company focused on the development and commercialization of innovative, minimally invasive solutions for patients with obstructive sleep apnea, announced today that its management team will present at the KeyBanc Capital Markets Healthcare Forum on Tuesday, March 18, 2025.
Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.
PHILADELPHIA, Feb. 17, 2025 (GLOBE NEWSWIRE) -- Kaskela Law LLC announces that it is investigating Inspire Medical Systems, Inc. (NYSE: INSP) (“Inspire Medical”) on behalf of the company's long-term shareholders.
The consensus price target hints at a 25.9% upside potential for Inspire (INSP). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.
Inspire Medical's both geographic segments witness strong revenue growth on the back of solid product demand in the fourth quarter.
Inspire Medical Systems, Inc. (NYSE:INSP ) Q4 2024 Earnings Conference Call February 10, 2025 5:00 PM ET Company Participants Ezgi Yagci - Vice President of Investor Relations Tim Herbert - President & Chief Executive Officer Rick Buchholz - Chief Financial Officer Conference Call Participants Travis Steed - Bank of America Securities Danielle Antalffy - UBS Robbie Marcus - JPMorgan Chris Pasquale - Nephron Research Anthony Petrone - Mizuho Financial Group Richard Newitter - Truist Securities David Rescott - Baird Adam Maeder - Piper Sandler Larry Biegelsen - Wells Fargo Shagun Singh - RBC Capital Markets Brett Fishbin - KeyBanc Capital Markets Jon Block - Stifel Michael Polark - Wolfe Research Mike Kratky - Leerink Partners Suraj Kalia - Oppenheimer & Co. Operator Good afternoon. My name is Dilem [ph] and I'll be your conference operator today.
Inspire Medical Systems (INSP -0.64%), known for its innovative devices that use neurostimulation to treat sleep apnea, announced impressive fourth-quarter results on Feb. 10. Earnings per share (EPS) came in at $1.15, well ahead of the $0.73 consensus estimate.
Although the revenue and EPS for Inspire (INSP) give a sense of how its business performed in the quarter ended December 2024, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers.